HomeGreater Than Icon
Jagsonpal Pharmaceuticals LtdGreater Than Icon
Jagsonpal Pharmaceuticals Ltd Financials
Company Logo

Jagsonpal Pharmaceuticals Ltd Financial Statement

Jagsonpal Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue76.35
Operating Expense58.41
Net Profit11.46
Net Profit Margin15.01
Earning Per Share4.29
EBIDTA16.71
Effective Tax Rate14.94

Jagsonpal Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual208.70
Operating Expenses Annual185.64
Operating Profit Annual32.35
Interest Annual0.81
Depreciation1.66
Net Profit Annual22.46
Tax Annual7.41

Jagsonpal Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning11.05
Cash Flow from Operations35.17
Cash Flow from Investing-24.55
Cash Flow from Financing-8.91
Cash Flow at the End12.76

Jagsonpal Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)15.50
PBIT Margin (%)14.70
PBT Margin (%)-3.45
Net PROFIT Margin (%)10.76
Return On Networth / Equity (%)12.97
Return On Networth /Employed (%)16.89
Return On Assets (%)12.38
Total Debt / Equity (X)0.04
Asset Turnover Ratio (%)1.15

Jagsonpal Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual9.30
Total Current Assets Annual199.25
Non Current Assets Annual17.82
Total Shareholders Funds Annual187.40
Total Assets Annual217.08

Jagsonpal Pharmaceuticals Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 5, 2024, Jagsonpal Pharmaceuticals Ltd has a market capitalization of 737.06 Cr. Value Research classifies it as a Small-Cap company.
Yes, Jagsonpal Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.05.
In FY 2023 , Jagsonpal Pharmaceuticals Ltd recorded a total revenue of approximately 208.70 Cr marking a significant milestone in the company's financial performance.
Jagsonpal Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.1% and -0.0% annually, respectively..
Jagsonpal Pharmaceuticals Ltd's current PE ratio is 32.82.
Jagsonpal Pharmaceuticals Ltd's ROCE averaged 19.1% from the FY ending March 2022 to 2024, with a median of 20.3%. It peaked at 21.4% in March 2023, reflecting strong capital efficiency over the period..
Jagsonpal Pharmaceuticals Ltd's latest EBIT is Rs. 30.68 Cr, surpassing the average EBIT of Rs. 30.94 Cr over the 5 years..